Jump to the main content block

Ling-Yu Wang

Ling-Yu Wang

Appointment : Assistant Professor

LabEpigenetic oncology

Education : Ph.D.

University/NationUniversity of California, Davis/ USA

Tel: 3989

E-mail : lywang@mail.cgu.edu.tw

Research website :

Research interests:

Our research interests center around comprehending the molecular mechanisms that underlie prostate cancer tumorigenesis and drug resistance, with the ultimate goal of identifying new potential therapeutic strategies for treating this cancer. Despite the advent of improved therapeutic options for advanced prostate cancer, the clinical benefits' durability is limited due to the inevitable development of resistance. Approximately one-quarter of resistant tumors undergo lineage reprogramming, transforming into a highly aggressive and deadly tumor type with a continuum of neuroendocrine features. Understanding the molecular mechanisms driving the development of therapy-induced neuroendocrine differentiated prostate cancer is crucial, and it necessitates in vitro cell models that closely replicate clinical features. The PI's lab boasts expertise in biochemistry, molecular and cell biology, as well as advanced epigenetic technologies. Utilizing these techniques, we've developed cell models that mimic drug resistance with clinical relevance to study the dysregulated gene expression profiles. Our recent research focuses on the evaluation of targeting the androgen receptor as an intervention strategy for advanced prostate cancer, with the scope ranging from investigating the noncanonical roles of the androgen receptor through epigenetic and metabolic aspects to the development and evaluation of PROTAC (proteolysis targeting chimera) as a potential therapeutic modality. We are also interested in understanding the interactions between mesenchymal stem cells and cancer cells in the tumor microenvironment that contribute to the progression of prostate cancer.


  1. Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, Lin YC, Jhang MR, Hwang CS, Hsu HC, Kung HJ, Wang LY*. 2023. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. EBioMedicine 90:104500.

2.   Hung C-L, Wang L-Y*, Fu C-W, Hsu H-C, Kung H-J. 2023. Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer. Cancer Research 83:LB133-LB133.

3.   Bui NN, Li CY, Wang LY, Chen YA, Kao WH, Chou LF, Hsieh JT, Lin H, Lai CH. 2023. Clostridium scindens metabolites trigger prostate cancer progression through androgen receptor signaling. J Microbiol Immunol Infect 56:246-256.

4.   Liu JS, Fang WK, Yang SM, Wu MC, Chen TJ, Chen CM, Lin TY, Liu KL, Wu CM, Chen YC, Chuu CP, Wang LY, Hsieh HP, Kung HJ, Wang WC. 2022. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. J Biomed Sci 29:29.

5.   Wang HJ, Pochampalli M, Wang LY*, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ. 2019. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene 38:17-32.

6.   Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, Hung YW, Wang WC, Chu CY, Hung CL, Changou CA, Yen Y, Kung HJ. 2017. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun 8:15874.

7.   Wang LY*, Hung CL, Chen YR, Yang JC, Wang J, Campbell M, Izumiya Y, Chen HW, Wang WC, Ann DK, Kung HJ. 2016. KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis. Cell Rep 16:3016-3027.

8.   Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW. 2016. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ 23:1886-1896.

9.   Shih JW, Wang LY, Hung CL, Kung HJ, Hsieh CL. 2015. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. Int J Mol Sci 16:28943-28978.

10. Hung CL, Wang LY*, Yu YL, Chen HW, Srivastava S, Petrovics G, Kung HJ. 2014. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A 111:18697-18702.

11. Chu CH, Wang LY*, Hsu KC, Chen CC, Cheng HH, Wang SM, Wu CM, Chen TJ, Li LT, Liu R, Hung CL, Yang JM, Kung HJ, Wang WC. 2014. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. J Med Chem 57:5975-5985.

12. Wang LY*, Kung HJ. 2012. Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/CCDH1. Oncogene 31:2907-2918.

13. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. 2010. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer 1:40-49.

14. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. 2008. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27:499-505.

15. Wang LY*, Shiozaki K. 2006. The fission yeast stress MAPK cascade regulates the pmp3+ gene that encodes a highly conserved plasma membrane protein. FEBS Lett 580:2409-2413.

16. Wang LY*, Shimada K, Morishita M, Shiozaki K. 2005. Response of fission yeast to toxic cations involves cooperative action of the stress-activated protein kinase Spc1/Sty1 and the Hal4 protein kinase. Mol Cell Biol 25:3945-3955.

17. Lin SJ, Wang LY, Huang YJ, Kuo ML. 2001. Effect of interleukin (IL)-12 and IL-15 on apoptosis and proliferation of umbilical cord blood mononuclear cells. Bone Marrow Transplant 28:439-445.

* First or corresponding authors

Book Chapters

  1. Ghosh P, Qui Y, Wang LY, Kung HJ. Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer. Molecular Oncology: Causes of Cancer and Targets for Treatment. ISBN: 9780521876629. Editors: Gelmann E, Sawyers C, and Rauscher III F. Cambridge University Press. 2014.
  2. Wang LY, Guo W, Kim K, Pochampalli M, Hung CL, Izumiya Y, Kung HJ. Histone demethylases in prostate cancer. Nuclear Signaling Pathways and Targeting Transcription in Cancer. ISBN: 978-1-4614-8039-6. Editor: Rakesh Kumar. Springer. 2013.

Click Num: